Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Biochemical bone markers are sensitive to the changes in bone turnover that result from treatment of postmenopausal osteoporotic women with antiresorptive therapies. Although information is available on the use of bone markers in monitoring therapy in groups of subjects, less is known regarding how...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical chemistry (Baltimore, Md.) Md.), 1999-07, Vol.45 (7), p.1009-1017
Hauptverfasser:	Kress, Barry C, Mizrahi, Isaac A, Armour, Karen W, Marcus, Robert, Emkey, Ronald D, Santora, Arthur C., II
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alendronate - therapeutic use Alkaline Phosphatase - blood Biological and medical sciences Bone and Bones - enzymology Bone Density Bones, joints and connective tissue. Antiinflammatory agents Drug Monitoring Female Humans Immunoassay Medical sciences Middle Aged Osteoporosis, Postmenopausal - blood Osteoporosis, Postmenopausal - drug therapy Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Biochemical bone markers are sensitive to the changes in bone turnover that result from treatment of postmenopausal osteoporotic women with antiresorptive therapies. Although information is available on the use of bone markers in monitoring therapy in groups of subjects, less is known regarding how these markers perform in individual patients. Serum bone alkaline phosphatase (bone ALP) concentrations, measured with the Tandem(R) Ostase(R) assay, were used to monitor the biochemical response of bone in postmenopausal women with osteoporosis receiving either 10 mg/day alendronate therapy (n = 74) or calcium supplementation (n = 148) for 24 months. Bone ALP decreased significantly from baseline at 3 months (P
ISSN:	0009-9147 1530-8561
DOI:	10.1093/clinchem/45.7.1009